Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Real World Evidence Solutions Market
5.1. COVID-19 Landscape: Real World Evidence Solutions Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Real World Evidence Solutions Market, By Component
8.1. Real World Evidence Solutions Market, by Component, 2023-2032
8.1.1. Services
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Data Sets
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Real World Evidence Solutions Market, By Application
9.1. Real World Evidence Solutions Market, by Application, 2023-2032
9.1.1. Drug Development & Approvals
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Medical Device Development & Approvals
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Reimbursement/Coverage & Regulatory Decision Making
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Post Market Safety & Adverse Events Monitoring
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Real World Evidence Solutions Market, By End-user
10.1. Real World Evidence Solutions Market, by End-user, 2023-2032
10.1.1. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Healthcare Payers
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Healthcare Providers
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Real World Evidence Solutions Market, By Therapeutic Area
11.1. Real World Evidence Solutions Market, by Therapeutic Area, 2023-2032
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cardiology
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Neurology
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Diabetes
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Psychiatry
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Respiratory
11.1.6.1. Market Revenue and Forecast (2020-2032)
11.1.7. Other therapeutic areas (Immunology, Gastroenterology, etc.)
11.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Real World Evidence Solutions Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Component (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
Chapter 13. Company Profiles
13.1. IQVIA
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. IBM
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. PPD Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Parexel International Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. PerkinElmer Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Icon Plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Oracle
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Syneos Health
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Cegedim Health Data
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Medpace
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms